AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$63.07
pos +0.25
+0.40%
Today's Range: 62.45 - 63.26 | ABBV Avg Daily Volume: 6,901,000
Last Update: 09/30/16 - 4:01 PM EDT
Volume: 7,281,672
YTD Performance: 6.47%
Open: $62.67
Previous Close: $62.82
52 Week Range: $45.45 - $68.12
Oustanding Shares: 1,628,542,359
Market Cap: 102,305,030,992
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 7
Moderate Buy 1 0 0 0
Hold 7 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.27 2.23 2.23 2.14
Latest Dividend: 0.57
Latest Dividend Yield: 3.63%
Dividend Ex-Date: 10/12/16
Price Earnings Ratio: 18.10
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
18.10 18.10 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
1.87% 15.92% 41.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 14.50 0.20 0.07
Net Income 190.00 0.00 -0.01
EPS 184.50 -0.10 -0.02
Earnings for ABBV:
EBITDA 8.37B
Revenue 22.86B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $1.20 $1.19 $4.81 $5.69
Number of Analysts 9 7 10 11
High Estimate $1.22 $1.23 $4.85 $6.01
Low Estimate $1.17 $1.14 $4.77 $5.35
Prior Year $1.13 $1.13 $4.29 $4.81
Growth Rate (Year over Year) 6.00% 5.31% 12.14% 18.23%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Bret Jensen

 | Sep 13, 2016 | 12:00 PM EDT
These stocks look good as seasonal volatility sets in.
By

Bret Jensen

 | Sep 12, 2016 | 11:00 AM EDT
Summer is definitely over; here's how to play this volatile market.
RMPIA
By

David Katz

 | Sep 9, 2016 | 7:00 AM EDT
If and when interest rates go up, this basket of stocks should continue to do well.

bearishAbbvie downgraded at JP Morgan

Sep 8, 2016 | 7:02 AM EDT
ABBV was downgraded from Overweight to Neutral, JP Morgan said. $73 price target. Valuation call, as the company lacks near-term catalysts.
RMPIA
By

Jim Cramer

 | Aug 29, 2016 | 6:00 AM EDT
The leadership is quite stark.
RMPIA
By

James Passeri

 | Aug 18, 2016 | 11:55 AM EDT

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

By

Bret Jensen

 | Aug 12, 2016 | 10:00 AM EDT
Small biotech tanked on weak earnings, but still seems promising.
RMPIA
By

David Katz

 | Aug 5, 2016 | 7:00 AM EDT
Rarely do investors get to buy these types of quality businesses at such discounted prices.
RMPIA
By

Bret Jensen

 | Aug 2, 2016 | 11:00 AM EDT
The sector seems to be rebounding after tumbling by more than 40%.
RMPIA
By

James Passeri

 | Aug 1, 2016 | 5:05 PM EDT
The drug maker continued to rally Monday.
On Wednesday of last week NFLX appeared headed for a deep breakdown.  The stock fell ...
We added this one Monday and mentioned it Tuesday right here in CC, we'll take it off the ...
The market is rebounding nicely after yesteday's sell-off.  Biotech has recaptured ha...
The Federal Reserve has made it relatively clear that they intend to raise interest rates...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.